Clinical Trial Update: Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of CT1812 in mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CT1812

Snippet

Sponsor: Cognition Therapeutics | Conditions: Alzheimer's Disease | Phase 1, Phase 2 | Status: COMPLETED